Skip to main content
Premium Trial:

Request an Annual Quote

Ronald Faris, Andrea Grant, and Jerry Williamson


Ronald Faris has been promoted to senior vice president of MultiCell Technologies, the Warwick, RI-based company announced last week.

MultiCell said that Faris will also retain his role as chief science officer and chairman of the company’s scientific advisory board. Faris has been employed by MultiCell since 1999. He is also an associate professor of pathology and pediatrics at Brown University and Rhode Island Hospital. He earned his PhD in nutritional toxicology from Cornell University, and held a postdoctoral fellowship at the MD Anderson Science Park Research Center.

Andrea Grant has been appointed as managing director of Galadeno, the new service unit of Galapagos Genomics, the Mechelen, Belgium-based company said last week (see News Scan, in this issue). Grant used to be Galapagos’ director of business development.

Jerry Williamson has been appointed as the new president of Biacore, replacing Thomas Wida, who is leaving the company, Biacore International said last week. Williamson joins the Uppsala, Sweden-based company from Beacon BioPartners, a consultancy focusing on the life sciences sector. Until recently, he was the president of Pyrosequencing.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.